
Objectives To characterize intraoperative neurophysiological monitoring in pediatric epilepsy surgery in a single tertiary center. Methods We reviewed intraoperative neurophysiological monitoring procedures during pediatric epilepsy surgeries at Meyer Children’s Hospital, Florence, Italy, from 2018 to 2025. Results We analyzed 39 procedures in 37 children with lesional epilepsy. Mean age at surgery was 9.4 years. All patients underwent a comprehensive presurgical workup. Frontal lobe resection was the most frequent surgery, and focal cortical dysplasia was the most common histopathology. Total intravenous anesthesia and neuronavigation were used routinely. Brain activity was monitored using intraoperative electroencephalography; motor function was assessed using motor evoked potentials, direct cortical and subcortical stimulation, and continuous electromyography; somatosensory and visual function were evaluated using somatosensory and visual evoked potentials, respectively. All responses remained stable throughout all procedures. We reached high mean transcranial (164.4 mA) and cortical (21.7 mA) stimulation thresholds, however, we observed only one intraoperative seizure (2.6%) following intraoperative bleeding. Mean follow-up after surgery was 30.9 months. Expected postoperative deficits occurred in 38.5% procedures (permanent in three patients). At last visit 66.7% of patients were seizure-free. Discussion In pediatric epilepsy surgery, intraoperative neurophysiological monitoring is safe even at high stimulation thresholds. Combining presurgical planning and intraoperative neurophysiological monitoring optimizes pediatric epilepsy seizure and functional outcomes.
Purpose Neurofeedback based on deep brain stimulation (DBS) recordings has been shown to enable people with Parkinson’s disease (PD) to voluntarily modulate pathological beta-oscillations in the subthalamic nucleus (STN). While previous studies suggested the feasibility of differential neurofeedback (up- vs. downregulation), their sample sizes were too small to provide definitive evidence that people with PD can differentially modulate beta oscillations through mental strategies alone. Here, we aimed to provide evidence for differential DBS neurofeedback control using a pooled, intra-individual design. Methods People with PD conducted differential neurofeedback experiments and tried to both increase and decrease abnormal STN beta-oscillations as compared to baseline (cognitive and motor rest). We pooled two previously published cohorts, to demonstrate differential neurofeedback learning. A linear mixed-effects model assessed the capacity of people with PD to differentially control beta-peak activity. Results Differential neurofeedback-control improved with training. We found a strong effect of neurofeedback on beta-oscillations for the clinically relevant downregulation, showing a reduction by about 22% as compared to baseline. However, even upregulation experiments resulted in beta-reductions as compared to baseline, where beta-activity was abnormally increased. Conclusion We present the first evidence for differential modulation of subthalamic beta-activity using a pooled, intra-individual design. We also found that upregulation experiments generally reduced beta-activity as compared to mental rest. Therefore, we propose that exaggerated subthalamic beta-oscillations could signal, or even promote, not only the lack of motor flexibility, but also the lack of cognitive flexibility seen in PD.
Objectives Electrical stimulation (ES) during stereoelectroencephalography (SEEG) plays a key role in functional mapping in drug-resistant epilepsy. In pediatrics, protocols must account for neurodevelopmental stage. Moreover, pediatric data remain scarce and protocols vary substantially across centers. Such heterogeneity limits comparability between studies and hinders the evaluation of stimulation efficacy and its prognostic value for postoperative functional deficits. This work aims to provide expert consensus to harmonize SEEG stimulation protocols in the pediatric population. Methods A multidisciplinary task force of French experts from French pediatric epilepsy surgery centers reviewed existing guidelines and integrated current knowledge from developmental neurosciences. Through consensus, pediatric-specific parameters and practices were defined. Results The task force establishes practical guidance for stimulation frequency, intensity, and duration adapted to children, with emphasis on safety, feasibility, and neurodevelopmental context. Suggested protocols are designed to optimize both epileptogenic zone (EZ) delineation and functional mapping while enabling multicenter comparability. Conclusion The proposed methods provide a framework for safe and effective pediatric SEEG stimulation. They aim to standardize clinical practice, improve presurgical evaluations, and support collaborative research in pediatric epilepsy surgery.
OBJECTIVES:To evaluate whether the deep learning model IGENet-TS, a time-domain convolutional neural network (CNN), can classify expert-selected EEG excerpts containing visible generalised epileptiform activity from genetic generalised epilepsy (GGE) versus normal healthy-control excerpts, and whether this selected-excerpt task generalises across centres. METHODS:We performed a retrospective selected-excerpt classification study of 455 routine 32-channel EEGs: 237 from Cuenca (107 GGE, 130 controls) for development and 218 from Bremen (106 GGE, 112 controls) for external testing. Each GGE recording contributed a 120-s resting-state segment containing at least one visible generalised discharge; controls contributed representative normal resting background. IGENet-TS analysed thirty non-overlapping 4-s windows per segment and averaged window probabilities to obtain a segment-derived label. RESULTS:Repeated 70:30 internal testing yielded sensitivity 98.15% (95% CI 97.52-98.78), specificity against healthy-control excerpts 97.95% (97.40-98.50), accuracy 98.04% (97.45-98.63), F1 98.05% (97.50-98.60) and AUC 0.98 (0.96-1.00). Externally, sensitivity was 97.02% (96.39-97.65), specificity against healthy-control excerpts 96.80% (96.19-97.41), accuracy 96.91% (96.24-97.58), F1 96.62% (95.97-97.27) and AUC 0.97 (0.95-0.99). DISCUSSION/CONCLUSION:The IGENet-TS model distinguished curated discharge-containing GGE excerpts from normal healthy-control excerpts with stable centre-separated performance. These results support technical feasibility for the selected-excerpt classification task, but do not validate unattended full-recording EEG interpretation or clinical workflow use.
Objective Persistent symptoms after SARS CoV-2 infection, often designated as "long COVID”, continue to be an ongoing health issue. Previously, we reported electromyography (EMG) and single fiber EMG (SFEMG) abnormalities in long COVID. This study aimed to assess the long-term neuromuscular manifestations of long COVID. Methods In this follow-up study, fifty patients (39 females and 11 males, mean age at baseline: 48.1 ± 9.3 years) with long COVID showing myopathic (EMG and/or abnormal SFEMG at diagnosis were re-evaluated. The disease duration was 1.2 ± 0.6 years at baseline. The mean follow-up interval was 1.38 years. Quantitative EMG (qEMG) was performed on the biceps brachii (BB), vastus medialis (VM), and tibialis anterior (TA), while SFEMG was performed on the extensor digitorum communis (EDC) and TA, at baseline and follow-up on the same muscles and side. EMG, SFEMG, and clinical scores were compared using paired parametric or nonparametric tests. Results Fatigue Assessment Scale (FAS) scores were unchanged (35.8 ± 7.7 vs 34.0 ± 9.4; p > 0.05). Motor unit potential (MUP) amplitudes and durations increased in BB, TA, and VM (p = 0.0001), while the frequency of polyphasic potentials remained unchanged (p > 0.05). SFEMG findings in TA and EDC were also unchanged (p > 0.05). At baseline, 78% of individuals showed myopathic qEMG and 54% abnormal SFEMG; at follow-up, 18% had myopathic qEMG, 56% abnormal SFEMG, and 40% showed normal EMG and SFEMG. Discussion Myopathic changes decreased over time; however, SFEMG abnormalities and clinical scores remained persistent. These findings suggest ongoing neuromuscular dysfunction, although other mechanisms may also contribute to persistent long COVID symptoms.